SEARCH BY
| Category | Company |
|---|---|
| Founded | 1916 |
| Sector | Life Science |
| Employees | 29,904 |
| Revenue | 15.4B AUD (2025) |
CSL is a manufacturer and marketer of pharmaceutical and diagnostic products, cell culture media and human plasma fractions. CSL was founded in 1916 and is based in Melbourne, Australia.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector: Life Science M&A | 3 of 4 |
| Type: Add-on Acquisition M&A Deals | 2 of 3 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2021 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-06-13 |
Wuhan Biological Products Research Institute Co.
Wuhan, China Wuhan Biological Products Research Institute Co. Ltd. develops, manufactures and commercialises plasma-derived products for the Chinese domestic market. This includes albumin, immunoglobulin (Ig) for IV injection, as well as several hyperimmune Ig products. The company also has an advanced pipeline of multiple coagulation factor products that it plans to launch in the coming years, including plasma-derived Factor VIII. In addition, Ruide owns four plasma collection centres and one manufacturing facility in Wuhan, Central China. |
Buy | $352M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-09-19 |
VarmX
Leiden, Netherlands VarmX is a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation. VarmX was founded in 2016 and is based in Leiden, Netherlands. |
Buy | $2.2B |
